Yangfan Hou1,2, Lei Dong1, Xiaolan Lu3, Haitao Shi1, Bing Xu1, Wenting Zhong4, Lin Ma1, Shuhui Wang1, Caifeng Yang5, Xinyi He1, Yidi Zhao6, Shenhao Wang7. 1. Department of Gastroenterology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China. 2. Pulmonary and Critical Care Medicine, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China. 3. Department of Gastroenterology, Shanghai Pudong Hospital, Shanghai, 201399, China. 4. International Medical Ward, Xi'an Jiaotong University Medical College First Affiliated Hospital, Xi'an, 710061, China. 5. Departments of Gastroenterology, Xi'an City First Hospital, Xi'an, 710002, China. 6. Emergency Department, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China. 7. Department of Gastroenterology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, 710004, China. 15829701022@163.com.
Abstract
BACKGROUND AND AIMS: Recent studies have shown that changes in the intestinal microbiota contribute to the pathogenesis of irritable bowel syndrome (IBS). This study aimed to investigate the characteristics of the fecal and intestinal mucosal microbiota in IBS patients, and the correlation between microbiota and clinical manifestations. METHODS: Fecal and intestinal mucosal samples were collected from 14 constipation-predominant IBS (IBS-C) patients, 20 diarrhea-predominant IBS (IBS-D) patients, and 20 healthy controls (HCs). 16S rRNA gene sequencing and fluorescence in situ hybridization were used for the analysis of samples. RESULTS: Community richness and diversity of the fecal microbiota in IBS patients were significantly reduced compared with the HCs. The mucosal samples in IBS patients showed decreased Bifidobacterium and increased Bacteroides caccae compared with HCs; Eubacterium and Roseburia were decreased in IBS-C patients and increased in IBS-D patients. A comparison of the fecal and mucosal microbiota in IBS patients showed significantly increased Bifidobacterium in fecal samples and a decrease in mucosal samples in IBS-C patients; Bacteroides caccae and Roseburia were significantly reduced in fecal samples and increased in mucosal samples of IBS patients. A correlation between microbiota and clinical manifestations in IBS patients showed that Bacteroides caccae and Roseburia in fecal samples and Bifidobacterium and Eubacterium in mucosal samples were associated with abdominal pain and distention. CONCLUSIONS: Distinct differences exist between the fecal and intestinal mucosal microbiota in IBS patients, with the changes in the latter appearing more consistent with the pathophysiology of IBS. Changes in intestinal microbiota were associated with the clinical manifestations in IBS.
BACKGROUND AND AIMS: Recent studies have shown that changes in the intestinal microbiota contribute to the pathogenesis of irritable bowel syndrome (IBS). This study aimed to investigate the characteristics of the fecal and intestinal mucosal microbiota in IBS patients, and the correlation between microbiota and clinical manifestations. METHODS: Fecal and intestinal mucosal samples were collected from 14 constipation-predominant IBS (IBS-C) patients, 20 diarrhea-predominant IBS (IBS-D) patients, and 20 healthy controls (HCs). 16S rRNA gene sequencing and fluorescence in situ hybridization were used for the analysis of samples. RESULTS: Community richness and diversity of the fecal microbiota in IBS patients were significantly reduced compared with the HCs. The mucosal samples in IBS patients showed decreased Bifidobacterium and increased Bacteroides caccae compared with HCs; Eubacterium and Roseburia were decreased in IBS-C patients and increased in IBS-D patients. A comparison of the fecal and mucosal microbiota in IBS patients showed significantly increased Bifidobacterium in fecal samples and a decrease in mucosal samples in IBS-C patients; Bacteroides caccae and Roseburia were significantly reduced in fecal samples and increased in mucosal samples of IBS patients. A correlation between microbiota and clinical manifestations in IBS patients showed that Bacteroides caccae and Roseburia in fecal samples and Bifidobacterium and Eubacterium in mucosal samples were associated with abdominal pain and distention. CONCLUSIONS: Distinct differences exist between the fecal and intestinal mucosal microbiota in IBS patients, with the changes in the latter appearing more consistent with the pathophysiology of IBS. Changes in intestinal microbiota were associated with the clinical manifestations in IBS.
Authors: Ami D Sperber; Dan Dumitrascu; Shin Fukudo; Charles Gerson; Uday C Ghoshal; Kok Ann Gwee; A Pali S Hungin; Jin-Yong Kang; Chen Minhu; Max Schmulson; Arkady Bolotin; Michael Friger; Tamar Freud; William Whitehead Journal: Gut Date: 2016-01-27 Impact factor: 23.059
Authors: Michael P Jones; Jan Tack; Lukas Van Oudenhove; Marjorie M Walker; Gerald Holtmann; Natasha A Koloski; Nicholas J Talley Journal: Clin Gastroenterol Hepatol Date: 2017-01-10 Impact factor: 11.382
Authors: Magnus Simrén; Hans Törnblom; Olafur S Palsson; Miranda A L van Tilburg; Lukas Van Oudenhove; Jan Tack; William E Whitehead Journal: Gut Date: 2017-01-19 Impact factor: 23.059
Authors: Daniel Pohl; Lukas Van Oudenhove; Hans Törnblom; Boris Le Nevé; Jan Tack; Magnus Simrén Journal: Clin Gastroenterol Hepatol Date: 2018-04-24 Impact factor: 11.382
Authors: Emeran A Mayer; Jennifer S Labus; Kirsten Tillisch; Steven W Cole; Pierre Baldi Journal: Nat Rev Gastroenterol Hepatol Date: 2015-08-25 Impact factor: 46.802